Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Epic Bio

Main focus: CRISPR-based epigenetic engineering

Company stage: Pre-clinical

Diseases (gene editing): Facioscapulohumeral Muscular Dystrophy (FSHD), Heterozygous Familial Hypercholesterolemia (HeFH), Alpha-1 Antitrypsin Deficiency (A1AD), Retinitis Pigmentosa 4 (RP4), Retinitis Pigmentosa 11 (RP11)

Genome editing tool: CRISPR activation/CRISPR inhibition

Funding stage: Private

Location: South San Francisco, CA, USA

Website: https://epic-bio.com/

Pipeline: https://epic-bio.com/pipeline/

Epic Bio is a start-up company focused on epigenetic engineering using the CRISPR-Cas system. The company holds an exclusive license to a Cas enzyme called CasMINI, which is the smallest and most deliverable dCas protein to date, which can then be engineered with a modulating protein to attain activating- or inhibitory effects.

Tags

HashtagEpic Bio

Company: Epic Bio
close
Search CRISPR Medicine